These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15129882)

  • 1. Statistical considerations for use of composite health-related quality-of-life scores in randomized trials.
    Vickers AJ
    Qual Life Res; 2004 May; 13(4):717-23. PubMed ID: 15129882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.
    Fiteni F; Pam A; Anota A; Vernerey D; Paget-Bailly S; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2015; 15(8):885-91. PubMed ID: 26027598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size and power estimation for studies with health related quality of life outcomes: a comparison of four methods using the SF-36.
    Walters SJ
    Health Qual Life Outcomes; 2004 May; 2():26. PubMed ID: 15161494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The analysis, interpretation, and presentation of quality of life data.
    Stephens R
    J Biopharm Stat; 2004 Feb; 14(1):53-71. PubMed ID: 15027500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Composite outcomes in randomized clinical trials: arguments for and against.
    Ross S
    Am J Obstet Gynecol; 2007 Feb; 196(2):119.e1-6. PubMed ID: 17306647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing outcomes on peritoneal and hemodialysis: a case study in the interpretation of observational studies.
    Davies SJ
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):24-30. PubMed ID: 17237887
    [No Abstract]   [Full Text] [Related]  

  • 7. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
    Bakal JA; Westerhout CM; Armstrong PW
    Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choice of test for comparing two groups, with particular application to skewed outcomes.
    White IR; Thompson SG
    Stat Med; 2003 Apr; 22(8):1205-15. PubMed ID: 12687651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data.
    Vickers AJ
    BMC Med Res Methodol; 2005 Nov; 5():35. PubMed ID: 16269081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size considerations for superiority trials in systemic lupus erythematosus (SLE).
    Moore AD; Joseph L
    Lupus; 1999; 8(8):612-9. PubMed ID: 10568897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting the results of patient reported outcome measures in clinical trials: the clinician's perspective.
    Schünemann HJ; Akl EA; Guyatt GH
    Health Qual Life Outcomes; 2006 Sep; 4():62. PubMed ID: 16973000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite outcomes in randomized trials: greater precision but with greater uncertainty?
    Freemantle N; Calvert M; Wood J; Eastaugh J; Griffin C
    JAMA; 2003 May; 289(19):2554-9. PubMed ID: 12759327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample sizes for cancer trials where Health Related Quality of Life is the primary outcome.
    Julious SA; Campbell MJ; Walker SJ; George SL; Machin D
    Br J Cancer; 2000 Oct; 83(7):959-63. PubMed ID: 10970702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative efficiency and sample size for cluster randomized trials with variable cluster sizes.
    You Z; Williams OD; Aban I; Kabagambe EK; Tiwari HK; Cutter G
    Clin Trials; 2011 Feb; 8(1):27-36. PubMed ID: 21163852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
    Weir CJ; Kaste M; Lees KR;
    Stroke; 2004 Sep; 35(9):2111-6. PubMed ID: 15243146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency.
    Sim J; Lewis M
    J Clin Epidemiol; 2012 Mar; 65(3):301-8. PubMed ID: 22169081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A practical limit to trials needed in one-person randomized controlled experiments.
    Alemi R; Alemi F
    Qual Manag Health Care; 2007; 16(2):130-4. PubMed ID: 17426611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.